Explore below for a different way to receive treatment with OPDIVO Qvantig under-the-skin injections (subcutaneous injection).

Potential OPDIVO® (nivolumab) user viewing treatment options for RCC on her phone.

Getting treatment for
advanced kidney
cancer (renal cell
carcinoma)

See how you may receive treatment as an intravenous (IV) infusion with OPDIVO or under-the-skin injections (subcutaneous injection) with OPDIVO Qvantig.

Actor portrayal.

Advanced kidney cancer (renal cell carcinoma)

OPDIVO + YERVOY

For certain adults with previously untreated kidney cancer that has spread (advanced RCC)

OPDIVO Qvantig

For certain adults with kidney cancer that has spread (advanced RCC), after completing combination treatment with intravenous OPDIVO + YERVOY

Advanced kidney cancer (renal cell carcinoma)

OPDIVO + CABOMETYX® (cabozantinib)

For certain adults with previously untreated kidney cancer that has spread (advanced RCC)

OPDIVO Qvantig + CABOMETYX

For certain adults with previously untreated kidney cancer that has spread (advanced RCC)

Previously treated advanced kidney cancer (renal cell carcinoma)

OPDIVO

For certain adults with kidney cancer (RCC) when your cancer has spread or grown after treatment with other cancer medications

OPDIVO Qvantig

For certain adults with kidney cancer (RCC) when your cancer has spread after treatment with other cancer medications

Hands perusing OPDIVO® (nivolumab) patient resources.

Helpful patient resources

Explore resources to help you along your treatment journey

Clinical trial results for OPDIVO® (nivolumab) and OPDIVO-based combinations.

Clinical trial results

Explore findings from clinical trials with OPDIVO and OPDIVO based combinations



466-US-2600089 04/26